KD Nutra is pleased to announce the completion of a clinical trial for its Move3™ omega-3 joint formulation. The trial has shown that Move3™ has a significant impact in sports performance and exercise recovery.
“This trial demonstrated important improvements in subjective measures of exercise recovery, as well as hard biomarkers of exercise-induced damage to joints,” noted Adam Ismail, Chief Strategy Officer of KD Pharma. “Importantly, the effects were not only seen shortly after the exercise event, but also sustained over the course of the trial, meaning weekend warriors and serious athletes alike should consider the product to protect their active lifestyles.”
Complete the form to discover more or attend our presentation at Hi China!